Core Viewpoint - The company has decided to extend the implementation deadlines for its fundraising investment projects, specifically the "Innovative Drug R&D Project" to December 2028 and the "Shanghai Junshi Biotech Headquarters and R&D Base Project" to June 2026, without changing the investment content or total amount [1][4][17]. Fundraising Basic Situation - The company was approved to issue 70 million A-shares at a price of RMB 53.95 per share, raising a total of RMB 3,776.5 million. After deducting issuance costs of RMB 31.7 million, the net amount raised was RMB 3,744.8 million, with actual funds received amounting to RMB 3,759.35 million [1][2]. Project Delay Details - The delay in the fundraising projects is based on the company's prudent assessment of the actual progress of the projects, with no changes to the project entities, fundraising purposes, or investment scale [4][17]. - The "Innovative Drug R&D Project" deadline is extended to December 2028 to enhance the efficiency and effectiveness of fund usage, considering the dynamic changes in the innovative drug industry and the company's strategic development [6][9]. - The "Shanghai Junshi Biotech Headquarters and R&D Base Project" deadline is extended to June 2026 due to the complexity of the construction and verification processes, ensuring quality and compliance with regulations [7][8]. Feasibility Analysis of Fundraising Projects - The company possesses excellent drug discovery and development capabilities, covering five major therapeutic areas, and has established a complete technical system for drug development and production [10][12]. - The company has a professional and experienced management and R&D team, with a focus on innovative drug development and a strong emphasis on intellectual property management [13][14]. Impact of Project Delay - The project delay is a cautious decision based on operational needs and actual project conditions, ensuring that it does not adversely affect the company's normal operations or shareholder interests [17][18].

Core Viewpoint - Sunshine Nuohong announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute, aiming to enhance asset operation efficiency and reduce management costs due to the subsidiary's long-term losses [1][2]. Group 1: Equity Transfer Details - Sunshine Nuohong's subsidiary, Beijing Nuohong Demai Pharmaceutical Technology Co., Ltd., signed an equity transfer agreement, selling 70% of its stake in Meisuke Data for 2 million yuan [1]. - After the transaction, Sunshine Nuohong will no longer hold any equity in Meisuke Data, which will be excluded from the company's consolidated financial statements [1]. - The transfer involves part of the fundraising project "Clinical Trial Service Platform Construction Project," which has been completed and is now operational [1]. Group 2: Financial Implications - Meisuke Data has accumulated fundraising of 17.2887 million yuan, with 4.5 million yuan being registered capital paid by Nuohong Demai [1]. - The remaining 12.7789 million yuan of the fundraising will be returned to Sunshine Nuohong's fundraising account for future investment in the "Innovative Drug R&D Project" [2]. - The company aims to improve operational efficiency and support business expansion through this equity transfer, which is a strategic decision based on the company's current situation [2].

Core Viewpoint - Haichuang Pharmaceutical announced adjustments to certain sub-projects within its "Innovative Drug R&D Project" to enhance the efficiency of fundraising, while keeping the total investment amount unchanged [2]. Group 1 - The company will hold its second board meeting and the tenth supervisory board meeting on August 13, 2025, to review the proposal for adjustments [2]. - The adjustments to the fundraising projects require approval from the company's shareholders' meeting [2].

Group 1 - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. convened a meeting to discuss and approve changes to the use of special fundraising accounts and the establishment of new accounts [1][2] - The company agreed to change the purpose of existing fundraising accounts from various research projects to focus on "large model platform projects for peptide molecules" and "innovative drug research projects" [1][2] - New special fundraising accounts will be established by the company's subsidiaries for specific projects, ensuring that the funds are used solely for their intended purposes [1][2] Group 2 - The board approved an adjustment to the grant price of the 2025 restricted stock incentive plan from 22.78 yuan per share to 22.62 yuan per share due to the company's annual equity distribution [2][3] - This adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [2][3] - The voting results for the incentive plan adjustment showed unanimous support from the board members present [4]